Zobrazeno 1 - 8
of 8
pro vyhledávání: '"J. P. Hatcher"'
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis
Autor:
J. M. Hatcher-Martin, J. L. McKay, A. F. Pybus, B. Sommerfeld, J. C. Howell, F. C. Goldstein, L. Wood, W. T. Hu, S. A. Factor
Publikováno v:
npj Parkinson's Disease, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract We explore the association between three Alzheimer’s disease-related and ten inflammation-related CSF markers and freezing of gait (FOG) in patients with Parkinson’s disease (PD). The study population includes PD patients with FOG (PD-FO
Externí odkaz:
https://doaj.org/article/924d91281f934f699f164f0dae6b1608
Publikováno v:
Psychopharmacology. 138:275-282
Sabcomeline, (SB-202026 [R-(Z)-alpha-(methoxyimino)-1 -azabicyclo [2.2.2] octane-3-acetonitrile]), a functionally selective muscarinic M1 receptor partial agonist, was tested in rats trained to perform a delayed, reinforced alternation task in a T ma
Autor:
J P Hatcher, J J Hagan
Publikováno v:
Psychopharmacology. 140(4)
The effects of the dopamine D3/D2 receptor agonists quinpirole, quinelorane and (+/-)7-OH-DPAT [(+/-) 7-hydroxy-2(N,N-di-n-propylamino) tetralin] on intracranial self-stimulation (ICSS) were investigated. Rats implanted with bipolar electrodes into t
Autor:
J M, Loudon, S M, Bromidge, F, Brown, M S, Clark, J P, Hatcher, J, Hawkins, G J, Riley, G, Noy, B S, Orlek
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 283(3)
The finding that ascending cholinergic systems are severely degenerated in Alzheimer's disease has driven the search for a cholinomimetic therapy. Adverse effects observed with cholinesterase inhibitors and high-efficacy muscarinic agonists led us to
Autor:
J. P. Hatcher, J. J. Hagan
Publikováno v:
Psychopharmacology. 134(4)
Autor:
M. Harries, Michael S. G. Clark, F. Brown, Julie Hawkins, Graham J. Riley, Loudon Julia Mary, J. P. Hatcher, G. Noy
Publikováno v:
Neurobiology of Aging. 17:S161
Publikováno v:
Neurobiology of Aging. 17:S30
Autor:
Paul Mitchell, J. Semple, Michael S. G. Clark, M. S. Hadley, D. S. Graves, J. P. Hatcher, William Campbell, Graham J. Riley, P. Needham, F. Brown
Publikováno v:
Psychopharmacology. 94
BRL 34778, exo-4-amino-5-chloro-2-methoxy-N-[9-(4-fluorophenylmethyl)-9-azabi cyclo(3.3.1) non-3-yl]-benzamide, is a very potent and specific dopamine D2-receptor antagonist. It exhibits a Ki value of 2.14 nM for dopamine D2-receptors but much lower